Johnson & Johnson announced on April 21 that it will debut its new CARTOSOUND SONATA system at the 2026 Heart Rhythm Society (HRS) conference in Irvine, California, scheduled for April 23‑26. The device is a CARTO‑powered, AI‑driven innovation that automatically converts intracardiac echocardiography images into detailed heart‑chamber maps, aiming to improve procedural efficiency and outcomes for electrophysiologists.
The launch marks the first public introduction of the device and expands J&J’s MedTech portfolio into a new segment of cardiac rhythm management. It aligns with the MedTech division’s focus on high‑growth cardiovascular and robotic markets and coincides with the 30th anniversary of the original CARTO System, underscoring the company’s long‑standing leadership in electrophysiology.
At the same conference, J&J presented new clinical data for its VARIPULSE Platform, a pulsed‑field ablation technology for atrial fibrillation, indicating a broader push to advance arrhythmia care across multiple product lines. The HRS 2026 conference, which attracts more than 10,000 attendees, provides a high‑profile venue for showcasing these innovations.
Company Group Chair Michael Bodner highlighted the system’s AI‑driven mapping capabilities and its potential to improve procedural efficiency and outcomes for electrophysiologists. The announcement signals J&J’s commitment to integrating advanced imaging and AI into its electrophysiology offerings.
The introduction of CARTOSOUND SONATA positions J&J to compete more aggressively in the electrophysiology market, where AI‑enabled mapping solutions are increasingly sought after. The product’s launch may broaden the company’s revenue base within MedTech and reinforce its strategy to capture growth in cardiovascular and robotic segments.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.